Table 2.

Efficacy of 255 patients with ALK rearranged non-small cell lung cancer enrolled in A8081001 and PROFILE 100527,29

Efficacy parameter	A8081001 (n = 119*)	PROFILE 1005 (n = 136)
ORR (CR + PR) [% (95% CI)]	61% (2% + 59%) [52%, 70%]	50% (1% + 49%) [42%, 59%]
Duration of response (months) [range]	11.22 (0.96–17.87)	9.78 (1.45–9.82)

^*Notes: 119 patients enrolled and 116 evaluable patients. Response rate was calculated based on 116 patients.

Abbreviations: CR, complete response; ORR, overall response rate; PR, partial response.